BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 18328540)

  • 1. The thrombolytic effect of miniplasmin in a canine model of femoral artery thrombosis.
    Fu J; Ren J; Zou L; Bian G; Li R; Lu Q
    Thromb Res; 2008; 122(5):683-90. PubMed ID: 18328540
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aspirin does not potentiate effect of suboptimal dose of the thrombin inhibitor inogatran during coronary thrombolysis.
    Chen LY; Nichols WW; Mattsson C; Teger-Nilson AC; Wallin R; Saldeen TG; Mehta JL
    Cardiovasc Res; 1995 Dec; 30(6):866-74. PubMed ID: 8746200
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention of early reocclusion after thrombolysis of copper coil-induced thrombi in the canine carotid artery: comparison of PEG-hirudin and unfractionated heparin.
    Rübsamen K; Hornberger W
    Thromb Haemost; 1996 Jul; 76(1):105-10. PubMed ID: 8819261
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of carboxypeptidase U (TAFIa) activity improves rt-PA induced thrombolysis in a dog model of coronary artery thrombosis.
    Björkman JA; Abrahamsson TI; Nerme VK; Mattsson CJ
    Thromb Res; 2005; 116(6):519-24. PubMed ID: 16181987
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intimatan (dermatan 4,6-O-disulfate) prevents rethrombosis after successful thrombolysis in the canine model of deep vessel wall injury.
    Hong TT; Van Gorp CL; Cardin AD; Lucchesi BR
    Thromb Res; 2006; 117(3):333-42. PubMed ID: 15893368
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antithrombotic efficacy of thrombin inhibitor L-374,087: intravenous activity in a primate model of venous thrombus extension and oral activity in a canine model of primary venous and coronary artery thrombosis.
    Cook JJ; Gardell SJ; Holahan MA; Sitko GR; Stump GL; Wallace AA; Gilberto DB; Hare TR; Krueger JA; Dyer DL; Sanderson PE; Vacca JP; Shafer JA; Lynch JJ
    J Pharmacol Exp Ther; 1999 Apr; 289(1):503-10. PubMed ID: 10087043
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Function of tissue-type plasminogen activator releaser on vascular endothelial cells and thrombolysis in vivo.
    Ueshima S; Matsuno H; Hayashi M; Horibuchi K; Okada K; Fukao H; Uematsu T; Matsuo O
    Thromb Haemost; 2002 Jun; 87(6):1069-74. PubMed ID: 12083488
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antithrombotic efficacy of single subcutaneous administration of a recombinant nematode anticoagulant peptide (rNAP5) in a canine model of coronary artery thrombolysis.
    Rebello SS; Blank HS; Lucchesi BR
    Thromb Res; 2000 Jun; 98(6):531-40. PubMed ID: 10899352
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A thrombosis model for evaluating thrombolytic agents in the guinea-pig: comparison of t-PA, scu-PA and a novel thrombolytic agent, staphylokinase, on thrombolytic activity.
    Hirata Y; Umemura K; Takiguchi Y; Uematsu T; Nakashima M
    Blood Coagul Fibrinolysis; 1993 Aug; 4(4):569-75. PubMed ID: 7692999
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Local proCPU (TAFI) activation during thrombolytic treatment in a dog model of coronary artery thrombosis can be inhibited with a direct, small molecule thrombin inhibitor (melagatran).
    Mattsson C; Björkman JA; Abrahamsson T; Nerme V; Schatteman K; Leurs J; Scharpé S; Hendriks D
    Thromb Haemost; 2002 Apr; 87(4):557-62. PubMed ID: 12008935
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inogatran, a novel direct low molecular weight thrombin inhibitor, given with, but not after, tissue-plasminogen activator, improves thrombolysis.
    Chen L; Nichols WW; Mattsson C; Teger-Nilsson AC; Saldeen TG; Mehta JL
    J Pharmacol Exp Ther; 1996 Jun; 277(3):1276-83. PubMed ID: 8667188
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hirudin and s18886 maintain luminal patency after thrombolysis with alfimeprase.
    Lee JY; Markland FS; Lucchesi BR
    J Cardiovasc Pharmacol; 2013 Feb; 61(2):152-9. PubMed ID: 23188127
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Changes in systemic fibrinolysis and blood coagulation parameters in local thrombolysis with tissue plasminogen activator (rt-PA)].
    Klein P; Roth FJ; Rieger H; Popov-Cenic S
    Vasa; 1992; 21(3):249-52. PubMed ID: 1529628
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The evaluation of plasmin and streptokinase activator complexes in a new rabbit model of venous thrombosis.
    Dupe RJ; English PD; Smith RA; Green J
    Thromb Haemost; 1981 Aug; 46(2):528-34. PubMed ID: 6458112
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Changes of blood coagulative and fibrinolytic system and function of pulmonary vascular endothelium after therapy in patients with acute pulmonary thromboembolism].
    Pang BS; Wang C; Lu Y; Yang YH; Xing GH; Mao YL; Huang XX; Zhai ZG
    Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(43):3074-8. PubMed ID: 18261355
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Turbulent axially directed flow of plasma containing rt-PA promotes thrombolysis of non-occlusive whole blood clots in vitro.
    Tratar G; Blinc A; Strukelj M; Mikac U; Sersa I
    Thromb Haemost; 2004 Mar; 91(3):487-96. PubMed ID: 14983224
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thrombolytic activity of a novel plasminogen activator, LY210825, compared with recombinant tissue-type plasminogen activator in a canine model of coronary artery thrombosis.
    Jackson CV; Crowe VG; Craft TJ; Sundboom JL; Grinnell BW; Bobbitt JL; Burck PJ; Quay JF; Smith GF
    Circulation; 1990 Sep; 82(3):930-40. PubMed ID: 2118431
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention of reocclusion by MCI-9038, a thrombin inhibitor, following t-PA-induced thrombolysis in a canine model of femoral arterial thrombosis.
    Mellott MJ; Connolly TM; York SJ; Bush LR
    Thromb Haemost; 1990 Dec; 64(4):526-34. PubMed ID: 2128137
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thrombolytic efficacy of native recombinant staphylokinase on femoral artery thrombus of rabbits.
    Li CJ; Huang J; Yang ZJ; Cao KJ
    Acta Pharmacol Sin; 2007 Jan; 28(1):58-65. PubMed ID: 17184583
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of PAI-039 [{1-benzyl-5-[4-(trifluoromethoxy)phenyl]-1H-indol-3-yl}(oxo)acetic acid], a novel plasminogen activator inhibitor-1 inhibitor, in a canine model of coronary artery thrombosis.
    Hennan JK; Elokdah H; Leal M; Ji A; Friedrichs GS; Morgan GA; Swillo RE; Antrilli TM; Hreha A; Crandall DL
    J Pharmacol Exp Ther; 2005 Aug; 314(2):710-6. PubMed ID: 15860572
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.